The Food and Drug Administration (FDA) has yet to approve any drugs containing cannabidiol (CBD). Reports of some CBD products containing contaminants such as pesticides and heavy metals have raised concerns for the use of CBD products. The FDA has not evaluated any unapproved CBD products, such as cosmetics, foods, products marketed as dietary supplements, or any other product (other than Epidiolex) that make therapeutic claims. The FDA has not had the opportunity to evaluate CBD residues in food or to establish an adequate abstinence period.
There are still many unanswered questions about the potential adverse reactions associated with CBD products and the risks associated with long-term use. This is an important part of the FDA's work because little is known about the amounts of CBD and several related cannabinoids, as well as the presence of toxic elements, pesticides, other potential chemical contaminants and adulterants that may be present in CBD products.
